Cybin Inc Ordinary Shares CYBN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024
-
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
-
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
-
Cybin Provides Corporate Update on Upcoming Clinical Milestones
-
Cybin Announces Completion of Previously Announced Share Consolidation
-
Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
-
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation
-
Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder
Trading Information
- Previous Close Price
- $9.25
- Day Range
- $8.86–9.35
- 52-Week Range
- $6.50–28.04
- Bid/Ask
- $8.81 / $9.24
- Market Cap
- $179.14 Mil
- Volume/Avg
- 93,059 / 182,043
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 50
- Website
- https://www.cybin.com
Comparables
Valuation
|
Metric
|
CYBN
|
MNMD
|
HRTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.01 | 1.87 | — |
Price/Sales | — | — | 2.22 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CYBN
|
MNMD
|
HRTX
|
|---|---|---|---|
Quick Ratio | 39.02 | 5.81 | 1.76 |
Current Ratio | 41.70 | 5.92 | 2.38 |
Interest Coverage | — | — | — |
Quick Ratio
CYBN
MNMD
HRTX
Profitability
|
Metric
|
CYBN
|
MNMD
|
HRTX
|
|---|---|---|---|
Return on Assets (Normalized) | −40.98% | −35.50% | −11.68% |
Return on Equity (Normalized) | −63.94% | −49.83% | — |
Return on Invested Capital (Normalized) | −44.68% | −49.35% | −18.15% |
Return on Assets
CYBN
MNMD
HRTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Nczktrwrf | Nybhf | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Gwncvcpn | Jnbkbh | $115.9 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Vhjlbmv | Xzthnw | $109.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zkrjtrllc | Tjrxbs | $34.2 Bil | |||
| argenx SE ADR
ARGX
| Nyyjckll | Ftnx | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Kqbnhzdt | Dbf | $28.9 Bil | |||
| Moderna Inc
MRNA
| Kvnfxjdq | Lpkxz | $22.6 Bil | |||
| United Therapeutics Corp
UTHR
| Fsbnzjmk | Lxxvr | $15.6 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Tkvqkrmf | Zgxvzt | $13.1 Bil | |||
| Incyte Corp
INCY
| Yqywyccl | Hmdbsr | $12.7 Bil |
United States